Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Iroko Selects Aptuit as Contract Manufacturing Partner for Phase III Lower-Dose NSAID Programs Formulated Using the SoluMatrix™ Nanotechnology Platform

Abstract:
Iroko Pharmaceuticals, LLC and Aptuit Inc. announced today that Aptuit will provide manufacturing scale-up services as Iroko progresses its novel pain medications to Phase III clinical trials.

Iroko Selects Aptuit as Contract Manufacturing Partner for Phase III Lower-Dose NSAID Programs Formulated Using the SoluMatrix™ Nanotechnology Platform

Philadelphia, PA and Greenwich, CT | Posted on May 4th, 2011

Under the services agreement, Aptuit will produce for Iroko Phase III supplies of lower dose, nanotechnology formulations for multiple nonsteroidal anti-inflammatory drugs (NSAIDs). Iroko has already completed Phase II studies for all of these products. Aptuit will also make batch material to satisfy requirements for product registrations.

While serving as a contract manufacturer, Aptuit will make use of the proprietary SoluMatrix™ technology of Iroko partner iCeutica Inc (recently acquired by Iroko on April 26, 2011 as announced in a previous press release). This nanoformulation technology makes possible the production of medications consisting of sub-micron, fast-dissolving drug particles.

John Vavricka, Iroko's Chief Executive Officer, commented, "Our strategic focus responds to the directive of the US Food and Drug Administration that NSAIDs should be used at the lowest effective dose for the shortest possible duration.1 We believe our patented nanoformulations will enable the development of NSAIDs at significantly lower doses without compromising onset of action or effectiveness. The consistent quality and attention to detail which Aptuit brings to its work will be an important resource as we advance these products toward the market."

"The confidence Iroko has placed in our ability to support them through this project as they progress their Phase III programs is a testament to the expertise of our team and the rigor of our science," said Timothy Tyson, Executive Chairman and Chief Executive Officer of Aptuit. "We look forward to working closely with Iroko to deliver a complete range of manufacturing services and to serve as a partner in advancing these important products."

####

About Iroko Pharmaceuticals, LLC
Iroko Pharmaceuticals, LLC is a pharmaceutical company committed to the development and commercialization of currently marketed pharmaceutical products in specialty therapeutic areas. Iroko is focused on the maximization of the revenue potential of these products through directed selling and marketing efforts and product-life-cycle management activities including development of new formulations to improve patient therapies. Iroko currently has several products under development using iCeutica's proprietary SoluMatrix™ Platform.

About Aptuit:
Aptuit Inc. is a global pharmaceutical services company focused on delivering contract development and manufacturing services and streamlining the drug development process for biotechnology and pharmaceutical innovators. Aptuit’s employees deliver an integrated suite of product development services to more than 800 companies worldwide, driven by a deep commitment to client service, quality and an unrivaled track record of scientific excellence. The company is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information about Aptuit, please visit www.aptuit.com, or for more information about Aptuit’s acquisition of the Verona Medicines Research Centre operations, please visit www.aptuit.com/Verona.

For more information, please click here

Contacts:
Iroko contact:
Phoenix IP Ventures
Lisa Gray, Managing Partner
267-765-3233

or
Aptuit contact:
Feinstein Kean Healthcare
Krystle Ficco
617-761-6702

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

GLOBALFOUNDRIES and Soitec Enter Into Long-term Supply Agreement on FD-SOI Wafers: Strategic milestone to help guarantee a secure, high-volume supply of FD-SOI technology September 20th, 2017

GLOBALFOUNDRIES Announces Availability of mmWave and RF/Analog on Leading FDX™ FD-SOI Technology Platform: Technology solution delivers ‘connected intelligence’ to next generation high-volume wireless and IoT applications with lower power and significantly reduced cost September 20th, 2017

GLOBALFOUNDRIES Announces Availability of Embedded MRAM on Leading 22FDX® FD-SOI Platform: Advanced embedded non-volatile memory solution delivers ‘connected intelligence’ by expanding SoC capabilities on the 22nm process node September 20th, 2017

Copper catalyst yields high efficiency CO2-to-fuels conversion: Berkeley Lab scientists discover critical role of nanoparticle transformation September 20th, 2017

Nanomedicine

Do titanium dioxide particles from orthopedic implants disrupt bone repair? September 16th, 2017

Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM(TM) Platform and Lead RNAi-based Drug Candidates September 14th, 2017

Graphene based terahertz absorbers: Printable graphene inks enable ultrafast lasers in the terahertz range September 13th, 2017

Applications for the nanomedTAB are open until September 18th, 2017 September 13th, 2017

Announcements

GLOBALFOUNDRIES Delivers 8SW RF SOI Technology for Next-Generation Mobile and 5G Applications: Advanced 8SW 300mm SOI technology enables cost-effective, high-performance RF front-end modules for 4G LTE mobile and sub-6GHz 5G applications September 20th, 2017

GLOBALFOUNDRIES Unveils Vision and Roadmap for Next-Generation 5G Applications: Technology platforms are uniquely positioned to enable a new era of ‘connected intelligence’ with the transition to 5G September 20th, 2017

GLOBALFOUNDRIES Delivers Custom 14nm FinFET Technology for IBM Systems: Jointly developed 14HP process is world’s only technology that leverages both FinFET and SOI September 20th, 2017

GLOBALFOUNDRIES Introduces New 12nm FinFET Technology for High-Performance Applications September 20th, 2017

Alliances/Trade associations/Partnerships/Distributorships

GLOBALFOUNDRIES and Soitec Enter Into Long-term Supply Agreement on FD-SOI Wafers: Strategic milestone to help guarantee a secure, high-volume supply of FD-SOI technology September 20th, 2017

GLOBALFOUNDRIES Unveils Vision and Roadmap for Next-Generation 5G Applications: Technology platforms are uniquely positioned to enable a new era of ‘connected intelligence’ with the transition to 5G September 20th, 2017

Leti and Partners in PiezoMAT Project Develop New Fingerprint Technology for Highly Reliable Security and ID Applications: Ultra-high Resolution Pressure Sensing Uses Matrices of Vertical Piezoelectric Nanowire To Reconstruct the Smallest Features of Human Fingerprints September 5th, 2017

Phenom-World selects Deben to supply a tensile stage as an accessory to their range of desktop SEMs August 29th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project